Troy M. Robinson, PhD

Biotech Equity Research Associate, Mizuho
GSK Student

Email

[email protected]

Dissertation

Interrogating Mutation Clonality and Cooperativity in Preleukemia and Measurable Residual Disease

Mentor

Ross L. Levine, MD

Start Year

2019

End Year

2025

Education

BS, University of California, Santa Barbara; Cancer Biology

Fellowships

  • Olayan Fellowship (2020-2021)
  • American Society of Hematology (2022-2023)
  • American Society of Hematology – Graduate Hematology Award (2022-2024)

Publications

Stahl M, Derkach A, Farnoud N, Bewersdorf JP, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel MA, Cai SF, Miles LA, Bowman RL, Geyer MB, Dunbar A, Epstein-Peterson ZD, McGovern E, Schulman J, Glass JL, Taylor J, Viny AD, Stein EM, Getta B, Arcila ME, Gao Q, Barker J, Shaffer BC, Papadopoulos EB, Gyurkocza B, Perales MA, Abdel-Wahab O, Levine RL, Giralt SA, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman MS, Roshal M, Goldberg AD. (2022) Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. Am J Hematol

Fortin J, Chiang MF, Meydan C, Foox J, Ramachandran P, Leca J, Lemonnier F, Li WY, Gams MS, Sakamoto T, Chu M, Tobin C, Laugesen E, Robinson TM, You-Ten A, Butler DJ, Berger T, Minden MD, Levine RL, Guidos CJ, Melnick AM, Mason CE, Mak TW; Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells.; Proceedings of the National Academy of Sciences of the United States of America; 2023; 120(4):e2208176120; PubMed ID: 36652477

Robinson TM, Levine RL; Oncogenic IDH1 Mutation Imparts Therapeutically Targetable Metabolic Dysfunction in Multiple Tumor Types.; Cancer discovery; 2023; 13(2):266-268; PubMed ID: 36744320

View a full listing of Troy M. Robinson’s journal articles.